On Wednesday, the biotechnology sector experienced a significant surge, specifically for companies focused on RNA-editing therapies, following impressive results from a clinical trial conducted by Wave Life Sciences Ltd. This trial demonstrated the potential of its innovative treatment aimed at a genetic disorder that leads to severe lung and liver complications. The company’s stock witnessed...
Premium Membership Required
You must be a Premium member to access this content.
Already a member? Log in here
